S. M. L. Abrams

461 total citations
19 papers, 337 citations indexed

About

S. M. L. Abrams is a scholar working on Oncology, Cardiology and Cardiovascular Medicine and Pharmacology. According to data from OpenAlex, S. M. L. Abrams has authored 19 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Cardiology and Cardiovascular Medicine and 4 papers in Pharmacology. Recurrent topics in S. M. L. Abrams's work include Drug Transport and Resistance Mechanisms (3 papers), Parathyroid Disorders and Treatments (3 papers) and Bone health and treatments (2 papers). S. M. L. Abrams is often cited by papers focused on Drug Transport and Resistance Mechanisms (3 papers), Parathyroid Disorders and Treatments (3 papers) and Bone health and treatments (2 papers). S. M. L. Abrams collaborates with scholars based in United Kingdom, Australia and Germany. S. M. L. Abrams's co-authors include L. R. I. Baker, Paolo Fanti, Marie–Claude Faugere, Hartmut H. Malluche, A. E. Johnston, Paul Turner, Richard A. Franklin, Roger Greenwood, W. R. Cattell and F. P. Marsh and has published in prestigious journals such as Kidney International, European Journal of Pharmacology and Age and Ageing.

In The Last Decade

S. M. L. Abrams

19 papers receiving 312 citations

Peers

S. M. L. Abrams

NEPHR

PFM

PPCH

ONCOL

Cristobal G. Duarte United States

Mary Chambers United States

Louis J. Riley United States

John Colman Australia

Karim Solangi United States

N. Van Landschoot Belgium

T. E. N. Jonassen Denmark

M.A. Valero Spain

Kübra Kaynar Türkiye

Annalisa Lucchesi Italy

Cristobal G. Duarte United States

S. M. L. Abrams

214 ×1.3

NEPHR

45 ×0.4

PFM

38 ×0.5

PPCH

33 ×0.7

ONCOL

92 ×2.0

Citations per year, relative to S. M. L. Abrams S. M. L. Abrams (= 1×) peers Cristobal G. Duarte

Countries citing papers authored by S. M. L. Abrams

Since Specialization

Citations

This map shows the geographic impact of S. M. L. Abrams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. M. L. Abrams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. M. L. Abrams more than expected).

Fields of papers citing papers by S. M. L. Abrams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. M. L. Abrams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. M. L. Abrams. The network helps show where S. M. L. Abrams may publish in the future.

Co-authorship network of co-authors of S. M. L. Abrams

This figure shows the co-authorship network connecting the top 25 collaborators of S. M. L. Abrams. A scholar is included among the top collaborators of S. M. L. Abrams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. M. L. Abrams. S. M. L. Abrams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Kulkarni, Spoorthy, Mark Glover, Vikas Kapil, et al.. (2022). Management of hypertensive crisis: British and Irish Hypertension Society Position document. Journal of Human Hypertension. 37(10). 863–879. 27 indexed citations

Johnston, A. E., et al.. (1996). Aspartame Pharmacokinetics—The Effect of Ageing. Age and Ageing. 25(3). 217–220. 4 indexed citations

Farthing, M.J.G., E M Alstead, S. M. L. Abrams, et al.. (1994). Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. Postgraduate Medical Journal. 70(823). 363–366. 18 indexed citations

Abrams, S. M. L., et al.. (1993). Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. European Journal of Clinical Pharmacology. 44(1). 63–67. 14 indexed citations

Raveendran, Ramasamy, Mark J. Caulfield, M Lawson, et al.. (1992). Indomethacin and Protein Binding of Methotrexate. Human & Experimental Toxicology. 11(4). 291–293. 5 indexed citations

Raveendran, Ramasamy, Mark J. Caulfield, S. M. L. Abrams, et al.. (1992). Protein binding of indomethacin, methotrexate and morphine in patients with cancer.. PubMed. 12(3). 117–22. 11 indexed citations

Lledo, Pierre‐Marie, S. M. L. Abrams, A. E. Johnston, & Rahel Pearson. (1990). Mexiletine pharmacokinetics and debrisoquine hydroxylator status. European Journal of Pharmacology. 183(6). 2393–2393. 3 indexed citations

Baker, L. R. I., et al.. (1989). 1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial. Kidney International. 35(2). 661–669. 127 indexed citations

Abrams, S. M. L., et al.. (1989). Pharmacokinetic Interaction Between Indoramin and Ethanol. Human Toxicology. 8(3). 237–241. 2 indexed citations

10.

Baker, L. R. I., et al.. (1989). Early therapy of renal bone disease with calcitriol: a prospective double-blind study.. PubMed. 27. S140–2. 19 indexed citations

11.

Abrams, S. M. L., et al.. (1988). Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite. European Journal of Clinical Pharmacology. 35(2). 195–198. 4 indexed citations

12.

Abrams, S. M. L., L. R. I. Baker, Peter Crome, et al.. (1988). Pharmacokinetics of flupirtine in elderly volunteers and in patients with moderate renal impairment. Postgraduate Medical Journal. 64(751). 361–363. 18 indexed citations

13.

Abrams, S. M. L., et al.. (1988). Pharmacodynamic and pharmacokinetic comparison of two formulations of lorazepam and placebo. Human Psychopharmacology Clinical and Experimental. 3(2). 133–138. 1 indexed citations

14.

Johnston, A. E., et al.. (1988). Circadian variation in theophylline absorption during chronic dosing with a slow release theophylline preparation and the effect of clock time of dosing.. British Journal of Clinical Pharmacology. 26(1). 73–77. 8 indexed citations

15.

Abrams, S. M. L., et al.. (1987). Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects. European Journal of Clinical Pharmacology. 32(6). 619–623. 10 indexed citations

16.

Abrams, S. M. L., et al.. (1986). The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers.. British Journal of Clinical Pharmacology. 21(4). 385–388. 14 indexed citations

17.

Baker, L. R. I., Jesse Muir, S. M. L. Abrams, et al.. (1986). Controlled trial of calcitriol in hemodialysis patients.. PubMed. 26(4). 185–91. 44 indexed citations

18.

Abrams, S. M. L., et al.. (1983). Effect of indoramin on human sperm motility.. British Journal of Clinical Pharmacology. 15(1). 127–128. 5 indexed citations

19.

Abrams, S. M. L., et al.. (1983). The effect of indoramin infusion on apparent liver blood flow in man.. British Journal of Clinical Pharmacology. 15(5). 576–578. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact